Trazodone and insomnia: a short-term benefit for perceived sleep, with uncertainties

Trazodone appears to improve self-reported sleep quality in the short term among people with insomnia symptoms. This is the finding of a meta-analysis of 13 randomized trials involving 1,366 participants. But results vary substantially between studies, and increasing the dose could offer little additional benefit while reducing tolerability.

Illustration of sleep and the assessment of its quality while taking trazodone.
SleepEditorial illustration, not study data.

What the researchers compared

This systematic review searched for randomized trials comparing trazodone with a placebo or comparing different doses of trazodone. Its primary outcome was subjective sleep quality—in other words, participants’ own assessment of their sleep. The researchers also examined treatment discontinuations, both for any reason and those attributed to adverse effects.

The dossier provides access only to the PubMed abstract, not the full text. It therefore does not allow a detailed account of each study population’s characteristics, the duration of each trial, or the adverse effects observed.

An average improvement, but highly variable results

Compared with placebo, the improvement in subjective sleep quality corresponds to a standardized effect size of 0.67, with a 95% confidence interval from 0.36 to 0.98. This measure allows assessments made using different scales to be pooled. It means neither a 67% improvement nor a specific number of extra minutes of sleep.

Statistical heterogeneity is high, with an I² of 80.86%. The average benefit therefore does not describe a uniform effect across all trials. The authors also report substantial clinical heterogeneity between the populations studied.

The relationship between dose and benefit remains exploratory

The modeling suggests that efficacy increases at low doses, then approaches a plateau. However, data at higher doses are sparse and imprecise. This curve is not enough to determine an optimal dose for any given person.

The conventional analysis finds no clear difference in treatment discontinuations, including those related to adverse effects. By contrast, the dose-response analysis suggests a possible increase in discontinuations due to adverse effects as the dose rises. These results therefore do not demonstrate tolerability equivalent to placebo.

Limitations to keep in mind

The interpretation is based solely on the abstract consulted. The populations are heterogeneous, high-dose data are limited, and long-term data are insufficient. Funding and conflicts of interest could not be verified in the dossier.

What we can take away

This review supports a short-term benefit for perceived sleep. It justifies neither automatic dose escalation nor a conclusion about the efficacy and safety of prolonged treatment.

Sources and provenance

Partager cet article

X f in

An error or a source to report? Contact the editorial team.